p53-independent p21 induction by MELK inhibition

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Maternal embryonic leucine-zipper kinase (MELK) is implicated in human carcinogenesis by promoting cell proliferation, inhibiting apoptosis, and maintaining stemness.
• MELK is recognized as a potential therapeutic target for various cancers.

Purpose of the Study:

• To investigate the effect of MELK inhibition on p21 expression in cancer cell lines, particularly those with TP53 mutations.
• To elucidate the mechanism by which MELK inhibition influences p21 expression and cell cycle progression.

Main Methods:

• Treatment of cancer cell lines with a potent MELK inhibitor (OTS167).
• MELK knockdown using small interfering RNA (siRNA).
• Analysis of p21 protein expression, cell cycle phase distribution, and phosphorylation of FOXO transcription factors.

Main Results:

• MELK inhibition (using OTS167 or siRNA) induced p21 protein expression in p53-deficient cancer cell lines.
• MELK inhibition led to cell cycle arrest at the G1 phase.
• FOXO1 and FOXO3, known p21 transcriptional regulators, were found to be phosphorylated by MELK, linking MELK activity to p21 induction.

Conclusions:

• MELK plays a role in regulating p21 expression, even in the absence of functional TP53.
• MELK inhibition represents a viable therapeutic approach for human cancers with TP53 mutations.
• The findings highlight a novel mechanism involving MELK, FOXO1/3, and p21 in cancer progression and treatment response.